However, investigation of SIRT2 expression by IHC in samples from 23 patients with glioblastoma (grade IV), eight patients with diffuse astrocytoma (grade II), and five healthy individuals revealed that SIRT2 preferential nuclear localization was more frequent in the malignant specimens, which was positively correlated with malignant progression (73). Here, SIRT2 is linked to diffuse astrocytoma.